Clinical trial · Observational
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
PET/MRI as a Predictor for Response to Preoperative Radiation Therapy and Chemotherapy in Resectable Rectal Cancer: a Pilot Study.
NCT01751516CI-TRIAL-00049709completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single arm, single center pilot study of 40 patients with uT3N0 or uT1-3N+ rectal cancer receiving pre-operative chemoradiation. Subjects will undergo PET/MRI scans before and after surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Carcinoma | Rectal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Negative post-chemoradiation PET/MRI scan, as correlated with surgical pathology
- timeFrame
- 4-8 weeks post-chemoradiation
Secondary outcomes (3)
- measure
- Recurrence-free survival
- timeFrame
- 5 years
- measure
- Disease-specific survival
- timeFrame
- 5 years
- measure
- Overall survival
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Low-lying, low- to moderate-risk pathologically-confirmed rectal cancer (stage uT3n) or uT1-3N+ * Negative workup for distant disease * \> 18 years of age * Pre-treatment workup completed including: * history and physical * CT or MRI of the abdomen and pelvis * endoscopic tumor evaluation (biopsy, blood work to assess CEA and hematopoietic, renal and liver function) * if female of child-bearing age, negative pregnancy test * Recommendation to undergo preoperative concurrent chemoradiation, as determined by the treating physician * Informed consent reviewed and signed Exclusion Criteria: * Not deemed a candidate for preoperative chemoradiation for medical reasons, such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus or cardiac disease * Hemoglobin ≤ 10.0 g/dL (transfusion allowed to achieve or maintain levels) * ANC ≤ 1,500/cubic mm³ * Platelet count ≤ 100,000/mm³ * ALT and AST ≥ 2.5 times upper level of normal (ULN) * Alkaline phosphatase ≥ 2.5 times ULN * Total bilirubin ≥ 1.5 times ULN * Creatinine clearance \< 50 mL/min * Creatinine ≥ 1.5 times ULN * Not deemed a candidate for concurrent preoperative chemoradiation for social reasons, such as psychiatric illness * Not deemed a surgical candidate * Currently active second malignancy, except non-melanoma skin cancer, non-invasive bladder cancer, low risk adenocarcinoma of the prostate and carcinoma in situ of the cervix * Previous pelvic radiation therapy * History of severe reaction to gadolinium * Inability to tolerate MRI (e.g., inability to lie flat for \> 1 hour) * Presence of a pacemaker, intracranial aneurysm clip, bladder stimulator, cochlear implant or metal near eyes * Body Mass Index (BMI) \> 35 * Pregnant or lactating female
References
Publications (0)
Data not yet available
No reference posted for this study.